Our view: Oral GLP-1 supplementation, combined with good nutrition and consistent habits, is the more evidence-supported non-prescription option
Regulatory & Safety: FDA Enforcement Report (2025): "Warning Letters regarding the marketing of unapproved and misbranded Retatrutide products." FDA.gov Eli Lilly and Company (2025): "Topline results for Retatrutide Phase 3 TRIUMPH Program." Lilly Investor Relations
1012 Artificial intelligence meets clinical trial design: A test case in predicting patient achievement of minimal significant difference using conditional generative adversarial networks Siddharth Kakked 1 1 OPEN Health, Falmouth, Maine, USA Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :1012 Aims This study investigates whether a conditional Generative Adversarial Network (cGAN) can reliably predict the probability of successfully achieving a clinical trial endpoint
Semaglutide is a GLP-1 receptor agonist that signals your brain to decrease hunger and slow stomach emptying, with clinical trials showing average weight loss of 1015% of body weight over 68 weeks
The fact that theres a medically approved prescription for managing weight and staying healthier, in my lifetime, feels like relief, like redemption, like a gift, and not something to hide behind and once again be ridiculed for
.jpg)
